How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

J Clin Oncol. 2017 Jul 10;35(20):2229-2231. doi: 10.1200/JCO.2016.71.8072. Epub 2017 May 4.

Authors

Petr Szturz¹, Tanguy Y Seiwert¹, Jan B Vermorken¹

Affiliation

¹ Petr Szturz, University Hospital Brno and Masaryk University, Brno, Czech Republic; Tanguy Y. Seiwert, The University of Chicago Medicine, and the University of Chicago Comprehensive Cancer Center, Chicago, IL; and Jan B. Vermorken, Antwerp University Hospital, Edegem, and University of Antwerp, Antwerp, Belgium.

PMID: 28471725
DOI: 10.1200/JCO.2016.71.8072

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cetuximab / adverse effects
Cetuximab / therapeutic use*
Clinical Decision-Making
Head and Neck Neoplasms / drug therapy*
Head and Neck Neoplasms / mortality
Head and Neck Neoplasms / pathology
Head and Neck Neoplasms / virology
Humans
Neoplasm Recurrence, Local
Papillomavirus Infections / virology
Risk Factors
Squamous Cell Carcinoma of Head and Neck / drug therapy*
Squamous Cell Carcinoma of Head and Neck / mortality
Squamous Cell Carcinoma of Head and Neck / secondary
Squamous Cell Carcinoma of Head and Neck / virology
Time Factors
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Cetuximab